Cargando…

Promoting benzodiazepine cessation through an electronically-delivered patient self-management intervention (EMPOWER-ED): Randomized controlled trial protocol

BACKGROUND: Long-term benzodiazepine dependence carries significant health risks which might be reduced with low-cost patient self-management interventions. A booklet version of one such intervention (Eliminating Medications Through Patient Ownership of End Results; EMPOWER) proved effective in a Ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Cucciare, Michael A., Hagedorn, Hildi J., Bounthavong, Mark, Abraham, Traci H., Greene, Carolyn J., Han, Xiaotong, Kemp, Lakiesha, Marchant, Kathy, White, Penny, Humphreys, Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468353/
https://www.ncbi.nlm.nih.gov/pubmed/36111174
http://dx.doi.org/10.1016/j.conctc.2022.100994
Descripción
Sumario:BACKGROUND: Long-term benzodiazepine dependence carries significant health risks which might be reduced with low-cost patient self-management interventions. A booklet version of one such intervention (Eliminating Medications Through Patient Ownership of End Results; EMPOWER) proved effective in a Canadian clinical trial with older adults. Digitizing such an intervention for electronic delivery and tailoring it to different populations could expand its reach. Accordingly, this article describes the protocol for a randomized controlled trial to test the effectiveness of an electronically-delivered, direct-to-patient benzodiazepine cessation intervention tailored to U.S. military veterans. METHODS: Design: Two-arm individually randomized controlled trial. SETTING: US Veterans Health Administration primary care clinics. PARTICIPANTS: Primary care patients taking benzodiazepines for three or more months and having access to a smartphone, tablet or desktop computer. INTERVENTION AND COMPARATOR: Participants will be randomized to receive either the electronically-delivered EMPOWER (EMPOWER-ED) protocol or asked to continue to follow provider recommendations regarding their benzodiazepine use (treatment-as-usual). MEASUREMENTS: The primary outcomes are complete benzodiazepine cessation and 25% dose reduction, assessed using administrative and self-report data, between baseline and six-month follow-up. Secondary outcomes are self-reported anxiety symptoms, sleep quality, and overall health and quality of life, measured at baseline and 6-month follow-up, and benzodiazepine cessation at 12-month follow-up. COMMENTS: This randomized controlled trial will evaluate whether the accessibility and effectiveness of a promising intervention for benzodiazepine cessation can be improved through digitization and population tailoring.